The shell is partially biodegradable and will not cause any harm to the body.
Researchers from the Massachusetts Institute of technology (MIT), together with colleagues from Harvard University and the pharmaceutical company Novo Nordisk created a mechanism that injects insulin directly into the mucosa of the stomach. It eliminates the need for permanent skin injections. This was reported on the website of the Institute, informs Rus.Media.
Diabetes type II diabetes – a disease in which the disruption of the interaction of insulin with cells of the tissues develops hyperglycemia, which is characterized by high glucose content in the blood serum. Such people have muscle weakness, dry mouth, itching and many other symptoms. To avoid further progression of the disease, they have to take insulin injections several times a day. A new invention can replace this process in the normal capsule that is taken orally.
Prior to this, scientists worked on a small ball covered with tiny needles through which received the drug. However, later they changed the form and left only one needle point and focused introduction.
The tip of the needle is made of almost completely compressed dried insulin. Her rod is not included in the wall of the stomach consists of another material, but is also biodegradable. Inside the capsule, the needle is held compressed by a spring, which is fixed by the disk of sugar. In the stomach, the water dissolves the sugar the disk, the spring is straightened and the needle enters the mucous membrane.
The capsule form is inspired by the leopard tortoise, which lives in Africa. Its shell resembles a cone because of this she is able to roll over on your stomach, if you flip it. Using computer modeling, the researchers experimented with form until I found one that allows the capsule to always navigate down the Foundation even in the dynamic environment of the stomach. As soon as the needle hits the wall, the insulin dissolves with the speed that when you create a capsule put scientists.
In experiments with pigs the authors were introduced to 0.3 mg of insulin. They later increased the dose to five milligrams. Now a collaboration of MIT and Novo Nordisk is working to optimize the manufacturing process. Experts believe that this method can be delivered to the organism a nucleic acid or any protein drug, for example, immunosuppressants.
Last year, researchers from ETH Zurich have created a technology which in the future will be able to replace regular insulin injections for diabetes. The subcutaneous implant is activated when the body is caffeine – that contains coffee or tea. The device has already been tested on mice predisposed to develop diabetes.